Agboyibor Clement, Dong Jianshu, Effah Clement Y, Drokow Emmanuel K, Pervaiz Waqar, Li Dié, Kang Lei, Ma Xinli, Li Jian, Liu Zhenzhen, Liu Hong-Min
School of Pharmaceutical Sciences, 12636Zhengzhou University, Zhengzhou, China.
Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education of China, 12636Zhengzhou University, Zhengzhou, China.
Cancer Control. 2021 Jan-Dec;28:10732748211051557. doi: 10.1177/10732748211051557.
Numerous studies on the prognostic significance of lysine-specific demethylase 1 (LSD1) up-regulation in tumors have different outcomes. The inconsistency originated from various studies looking into the association between LSD1 and tumor cells has prompted the decision of this quantitative systematic review to decipher how up-regulated LSD1 and overall survival (OS) or recurrence-free survival (RFS) or disease-free survival (DFS) are linked in tumor patients.
Articles were searched from online databases such as Embase, , PubMed, Google Scholar, and Scopus. The extraction of the hazard ratios (HR) with their 95% confidence intervals () was attained and survival data of 3151 tumor patients from 17 pieces of related research were used for this meta-analysis.
To shed light on the link between LSD1 up-regulation and the prognosis of diverse tumors, the pooled hazard ratios (HRs) with their 95% confidence intervals () were determined. In this meta-analysis, it was observed that LSD1 up-regulation is linked with poor OS (HR = 2.08, 95% : 1.66-2.61, P < .01) and RFS (HR = 3.09, 95% : 1.81-5.26, P < .01) in tumor patients. However, LSD1 up-regulation was not linked to DFS (HR = 1.49, 95% : .83-2.69, P = .18) in tumor patients. The subcategory examination grouped by tumor type and ethnicity showed that LSD1 up-regulation was linked with a poor outcome in the esophageal tumor and hepatocellular carcinoma and Asian patients, respectively. For clinical-pathological factors, up-regulated LSD1 was significantly linked with Lymph node status.
Despite the shortfall of the present work, this meta-analysis proposes that LSD1 up-regulation may be a prognostic biomarker for patients with tumors including esophageal tumors and hepatocellular carcinoma. We propose that large-scale studies are vital to substantiate these outcomes.
关于赖氨酸特异性去甲基化酶1（LSD1）上调在肿瘤中的预后意义，众多研究结果各异。对LSD1与肿瘤细胞之间关联的各项研究存在不一致性，这促使本定量系统评价来解读LSD1上调与肿瘤患者总生存期（OS）、无复发生存期（RFS）或无病生存期（DFS）之间的联系。
从Embase、PubMed、谷歌学术和Scopus等在线数据库中检索文章。获取风险比（HR）及其95%置信区间（CI），并将来自17项相关研究的3151例肿瘤患者的生存数据用于该荟萃分析。
为阐明LSD1上调与不同肿瘤预后之间的联系，确定了合并风险比（HR）及其95%置信区间（CI）。在这项荟萃分析中，观察到LSD1上调与肿瘤患者的不良OS（HR = 2.08，95%CI：1.66 - 2.61，P <.01）和RFS（HR = 3.09，95%CI：1.81 - 5.26，P <.01）相关。然而，LSD1上调与肿瘤患者的DFS无关（HR = 1.49，95%CI：0.83 - 2.69，P = 0.18）。按肿瘤类型和种族分组的亚类分析表明，LSD1上调分别与食管肿瘤、肝细胞癌患者及亚洲患者的不良预后相关。对于临床病理因素，LSD1上调与淋巴结状态显著相关。
尽管本研究存在不足，但该荟萃分析表明，LSD1上调可能是包括食管肿瘤和肝细胞癌在内的肿瘤患者的预后生物标志物。我们建议开展大规模研究以证实这些结果。
